THERAPY DOSSIER · th-b8a8342176f5

Heptanol (with N-acetylcysteine as a comparator antioxidant)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31601792 ↗2019Reported benefit

Inhibition of gap junction composed of Cx43 prevents against acute kidney injury following liver transplantation.

MixedIschaemia-reperfusionHepaticSprague-DawleyMaleIntraperitonealHeptanol 0.1 mg/kg; N-acetylcysteine 200 mg/kg1 hour before liver transplantation (pretreatment)

Model: Autologous orthotopic liver transplantation with an anhepatic phase of about 20 plus or minus 1 minutes followed by reperfusion

Heptanol pretreatment inhibited connexin 43 gap junction function and attenuated acute kidney injury after autologous orthotopic liver transplantation, improving creatinine, blood urea nitrogen and tubular histology and reducing oxidative stress, inflammatory cytokines and necroptosis markers, with…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…